Trials / Not Yet Recruiting
Not Yet RecruitingNCT07313852
A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
A Phase II Study of Concurrent Inotuzumab and Subcutaneous Blinatumomab in Older or Unfit Adult Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blinatumomab Injection | Blinatumomab given via subcutaneous injection |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2026-01-02
- Last updated
- 2026-02-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07313852. Inclusion in this directory is not an endorsement.